Drug intelligence / Profile preview

Tegiol

Development stage: Preclinical
Administration: Oral, Nasogastric, Enteral, Intravenous

Overview

Tegiol is a drug that has been investigated in the treatment of platinum-resistant recurrent ovarian cancer. In a systematic review and network meta-analysis, the co-administration of Tegiol with apatinib significantly improved the objective response rate (ORR) compared with apatinib monotherapy. Further details regarding its specific mechanism of action, developers, or manufacturers are not available from the provided context or external search results.

Other names: Tegiol

Beyond the preview

Go deeper on Tegiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tegiol.